SUMMIT THERAPEUTICS INC
SUMMIT THERAPEUTICS INC logo
SMMT

SUMMIT THERAPEUTICS INC (SMMT)

$3.271.24%

Market is closed
– opens on 8 PM, 31 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$2.9501
Day's Range
$3.27
$0.66
52-Week Range
$5.78
1 month return34.6%
3 month return200.0%
1 year return48.64%
5 year return4.94%

Analyst Recommendation

based on 6 analysts ratings

Sell
0%
Buy
50%
Hold
50%
Sell

Based on 6 Wall street analysts offering stock ratings for SUMMIT THERAPEUTICS INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 52.91%

Current

$3.27

Target

$5.0

Recommendation Trend

Based on 6 analyst

Current1M Ago3M Ago
Buy
0
0
0
Hold
3
3
3
Sell
3
3
3
Consensus
SELL
SELL
SELL

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization647.7M
Book Value$0.66
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-0.96
PEG Ratio0.0
Wall Street Target Price5.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)5.92
Enterprise Value671.6M
Enterprise Value/Revenue702.48
Enterprise Value/Ebitda-8.11

Technicals

Beta-1.0
50 Day MA3.15
200 Day MA1.67

Institutional Holdings

Vanguard Group Inc

0.39%

Millennium Management LLC

0.21%

BlackRock Inc

0.21%

Morgan Stanley - Brokerage Accounts

0.17%

Geode Capital Management, LLC

0.16%

Marshall Wace Asset Management Ltd

0.07%

Company Information

Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader in patient and physician friendly paradigm shifting antibiotic innovation. Its new mechanism antibiotics are designed to become the patient-friendly, new era standard-of-care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious disease, initially focussing on Clostridioides difficile infections ("CDI") which is estimated to impact over 3 million patients worldwide annually. Commercialization of ridinilazole for the treatment of CDI is subject to regulatory approvals. The overriding objective of Summit Therapeutics is to create value for patients, hospital infectious disease care givers, community based infectious disease healthcare providers, as well as healthcare payors around the world. Currently, Summit's lead product candidate ridinilazole is engaged in two global phase III trials, Ri-CoDIFy 1 & 2, each enrolling 680 patients vs standard of care (Vancomycin) for the treatment of C. difficile infections.
OrganizationSUMMIT THERAPEUTICS INC
Employees105
CEOMr. Robert W. Duggan
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is SUMMIT THERAPEUTICS INC share price today?

Can Indians buy SUMMIT THERAPEUTICS INC shares?

How can I buy SUMMIT THERAPEUTICS INC shares from India?

Can Fractional shares of SUMMIT THERAPEUTICS INC be purchased?

What are the documents required to start investing in SUMMIT THERAPEUTICS INC stocks?

What are today’s High and Low prices of SUMMIT THERAPEUTICS INC?

What are today’s traded volumes of SUMMIT THERAPEUTICS INC?

What is today’s market capitalisation of SUMMIT THERAPEUTICS INC?

What is the 52 Week High and Low Range of SUMMIT THERAPEUTICS INC?

How much percentage SUMMIT THERAPEUTICS INC is down from its 52 Week High?

How much percentage SUMMIT THERAPEUTICS INC is up from its 52 Week low?

What are the historical returns of SUMMIT THERAPEUTICS INC?

Who is the Chief Executive Officer (CEO) of SUMMIT THERAPEUTICS INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*